Souhaitez-vous accéder aux communiqués récents ?

Data spans seven presentations across both solid tumors and hematologic malignancies, providing updates on the potential benefit these therapies may bring to patients. Data from the elacestrant plus...

NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of...

Prenetics records Q1 2026 revenue of $36.0 million with IM8 revenue of $33.8 million, up 23.1% from IM8 revenue of $27.4 million in Q4 2025Raises full-year 2026 IM8 revenue guidance to $190 million to...

OrganOx Appointments Naoya Iwata as CEO & President. Craig Marshall and Rupa Basu will both continue to support OrganOx in advisory roles.

Woburn, MA, May 14, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI) (the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic...

New immunologic and biomarker data supports the potential of ITK inhibition with soquelitinib to increase persistent Treg cells and influence multiple inflammatory pathways. Data supports potential...

NETSOL Technologies reports record quarterly revenue and 13% year-over-year growth in Q3 fiscal 2026.

FENNEC PHARMACEUTICALS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

FORT WASHINGTON, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Toll Brothers, Inc. (NYSE: TOL) (TollBrothers.com), the nation’s leading builder of luxury homes, today announced that Seth J. Ring, Executive...

5,708,665 Shares Tendered Within the Initial Acceptance Period, bringing Total Secured Shares to approximately 81.3% of outstanding Northern Data Shares Additional Acceptance Period Commences on May...